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1. Introduction 
It has been shown [l-3] that labelled y-buty- 
robetaine administered to animals was rapidly trans- 
formed to carnitine. The reaction was catalyzed by 
an enzyme (ybutyrobetaine hydroxylase, 
EC 1.14.11 .l) in the soluble fraction of rat liver 
homogenates [4-61. In recent work with normal and 
diabetic human liver (unpublished) we have also 
recovered this enzymic activity in the soluble fraction 
of cell homogenates. It was shown [S] that homog- 
enates from rat liver but not from muscle or kidney 
hydroxylated y-butyrobetaine to carnitine, and no 
conversion of y-butyrobetaine to carnitine was found 
[7] , when the liver was excluded from the circulation. 
The ability of rat liver, kidney, muscle, heart and 
testis to form carnitine in vitro was tested [8]. All 
tissues carried out the synthesis of y-butyrobetaine 
from trimethyllysine, but only liver tissue, and to a 
limited extent also testis tissue, formed carnitine. 
These studies suggested that, in the rat, the liver is the 
main site of the conversion of y-butyrobetaine to 
camitine. 
It was reported [9] that ovine kidney and skeletal 
muscle but not heart muscle had the ability to form 
carnitine from y-butyrobetaine. Although the activity 
of y-butyrobetaine hydroxylase in skeletal muscle was 
only 1/3rd of that in the liver calculated per g soluble 
protein, the major portion of the total hydroxylase 
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activity of the body would be present in the skeletal 
muscle. This finding implied that the present concept 
that carnitine is transported to muscle rather than 
synthesized within this tissue is incorrect. Ovine [lo] 
and human skeletal muscle [ 111 have a very high 
camitine concentration compared to rat [ 11 ,121 and 
mouse muscle [ 131. In man and sheep, the carnitine 
concentration in heart muscle is lower than in the 
skeletal muscle [ 10,131 in contrast to what is found 
in the rat [ 121. In view of these species differences, 
it was of interest to examine human skeletal muscle 
for y-butyrobetaine hydroxylase activity; we also 
attempted to demonstrate such activity in ovine 
skeletal muscle. 
2. Experimental procedures 
2.1 .Materials 
y-Butyrobetaine chloride was obtained from 
E. Merck AG, Darmstadt. y-[methyl-‘4C3]Butyrobetaine 
was synthesized as in [S] . 
2.2. Sources of tissues 
Four female patients were studied, age 18,35,48 
and 75 years. They were admitted to the hospital for 
operation of inguinal hernia or uncomplicated gall- 
stone disease. Three liver biopsies [ 141 and four 
muscle biopsies from rectus abdominis and gastroc- 
nemius muscles were taken [ 151. The patients had no 
evidence of liver damage as judged from the deter- 
mination of serum concentration of bilirubin, 
aspartate and alanine aminotransferases, and alkaline 
57 
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phosphatase. Informed consent was obtained from all 
patients. The sheep were 1 S-3 years old. Tissue 
samples were taken from liver and the tibialis anterior 
muscle as soon as possible after death. Visible fat and 
fascia was rapidly removed from the specimens, which 
were placed immediately in ice-cold 0.25 mol/l 
sucrose. The procedure lasted 1.5-30 min. 
2.3. Preparation of tissue extracts 
Homogenates were prepared in cold 0.25 mol/l 
sucrose in a Potter-Elvehjem homogenizer with a glass 
or a Teflon pestle under cooling. The concentration 
(wet wt/vol.) was: 33% for liver tissue, 25% for 
human muscle, 17% and 33% for sheep muscle tissue. 
The homogenates from human muscle were first 
centrifuged at 800 X g for 10 min, then at 
100 000 X g for 1 h. The homogenates from sheep 
muscle, as well as human and sheep liver were 
centrifuged at 100 000 X g for 1 h. One 100 000 X g 
supernatant fraction from sheep muscle was dialyzed 
against saturated (N&),S04 for 15 h. The precipitate 
was dissolved in 50 mmol/l potassium phosphate 
buffer (pH 7 .O) before enzyme assay. 
2.4. Enzyme assay 
y-Butyrobetaine hydroxylase activity was assayed 
essentially as in [6]. The composition of the incubation 
mixture, unless otherwise specified, was: 2-0x0- 
glutarate, 7.1 mmol/l; FeS04, 0.6 mol/l; sodium 
ascorbate, 14 mmol/l; catalase, 1.4 g/l; potassium 
phosphate buffer (pH 7 .O), 14 mmol/l. The total 
volume was 0.7 ml. For amount of y- [methyG14C3] - 
butyrobetaine and protein in the experiments with 
the 100 000 X g supernatant fractions, see table 1. 
The same amounts of labeled y-butyrobetaine and 
comparable volumes of tissue homogenate were used 
in the experiments with unfractionated homogenates 
or the 800 X g supernatant fractions. The incubations 
were carried out at 37°C for 30 min or 60 min and 
were terminated by the addition of 0.5 ml 10% (w/v) 
trichloroacetic acid. After cooling in ice for 1 h the 
suspension was centrifuged and the supernatant frac- 
tion was put onto a column of Dowex AC 50W X8 
(1.5 X 7.5 cm, 13.2 ml), which was eluted with 
1 mol/l HCl. The eluate was collected in fractions of 
60 ml, 40 ml (containing carnitine), 3 X 10 ml and 
120 ml. The amount of radioactivity was determined 
in 300 ~1 portions of the fractions using a liquid 
58 
Table 1 
r-[methyl-‘4C,]Butyrobetaine and protein content in the 
incubations with the 100 000 X g supernatant fractions 
of tissue homogenates 
Samples Labelled y-butyrobetaine Protein 
(mg) 
(mmol/l) (ma/l) 
Human liver 0.1 0.4 1.4-2.0 
Human muscle 0.03 0.8 0.3-3.0 
Sheep liver l-3 0.1 0.8-0.9 2.5-2.9 
Sheep liver 4-5a 0.7 0.8-0.9 4.0-5 .o 
Sheep muscle l-3 0.7 0.8-0.9 0.2-0.7 
Sheep muslce 4-Sa 0.03 and 0.2 0.9 2.6-2.8 
Sheep muscle 4-5apb 0.03 and 0.2 0.9 2.9-4.9 
a FeSO,, 1 mmol/l, and KCl, 20 mmol/l, otherwise as 
specified in section 2 
b Ammonium sulphate fractions 
scintillation spectrometer. In the experiments with 
muscle tissue, the fraction containing carnitine was 
taken to dryness with a rotatory evaporator and 
redissolved in a small volume of water before measure- 
ment of radioactivity. The blank contained all com- 
ponents except for tissue extract and was carried 
through the whole procedure. The detection limit for 
enzymic formation of carnitine varied between 0.3% 
and 1 .O% conversion of the substrate in different 
experiments. Protein was determined by the Lowry 
method with bovine albumin as standard and in the 
ammonium sulphate fractions by ultraviolet absorp- 
tion [16]. 
3. Results and discussion 
The formation of carnitine from y-butyrobetaine 
in the 100 000 X g supernatant fraction of sheep or 
human liver was linear with time during 60 min and 
with the concentration of liver tissue extract (fig.1). 
The specific activity of y-butyrobetaine hydroxylase 
in human liver was of the same order of magnitude as 
in ovine liver (table 2). An activity of 4.2 nkat X 
(g protein)-’ in ovine liver was reported [9] *, which 
is similar to that found by us. A liver hydroxylase 
activity was found in a 70 000 X g supernatant from 
two patients with carnitine deficiency of 2.4 and 
5.4 nkat X (g protein)-’ [ 17]*, respectively, whereas 
* Recalculated from the authors’ data 
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Fig.1. {A) Formation of carnitine from r-butyrobetaine 
after different incubation times, using the 100 800 X g 
supernat~t fraction of sheep liver homogenate containing 
4 mg (o-o) or 5 mg (02) protein. (B) Formation of 
carnitine from -r-butyrobetaine in incubations with differ- 
ent amounts of sheep liver tissue extracts. The protein 
concentration in the 100 000 X g supernatants was 25 g/l 
(e---e) or 29 g/l (o-o), respectively. 
the activity in liver tissue obtained from autopsy 
material in three cases was 2.2; 2.7 and 3 .l nkat X 
(g protein)-‘, respectively. 
No r-butyrobetaine hydroxylase activity (i.e., 
< 0.04 nkat X fg protein)-‘) could be demonstrated 
Table 2 
~-Butyrobeta~e hydroxylase activity in liver tissue extracts 
Sample Specific activity 
nkat X (g protein)-’ 
Sheep Human 
1 3.5 5.7 
2 4.5 11 
3 5.1 12 
4 8.3 
5 11 
Homogenates (33%) were prepared in 0.25 mol/l sucrose and 
centrifuged at 100 000 X g for 1 h. The su~rnatant fractions 
were assayed for enzyme activity, using -y-[merhyl-t4C,)- 
butyro~taine as substrate 
in homogenates from human skeletal muscle, neither 
in the 800 X g supematant or in the 100 000 X g 
supernatant fractions. This finding prompted us to 
assay the hydroxylase activity in sheep muscle. In the 
first experiments ( heep muscle, samples l-3), no 
enzyme activity was found in the unfractionated 
homogenates or in the 100 000 X g supematant frac- 
tions. In the next experiments ( heep muscle tissue 
4-51, the assay was performed also with lower mass 
concentrations of y-butyrobetaine with higher specific 
radioactivity and more tissue extract (table 1). In 
these experiments, we only tested the 100 000 X g 
supernatant fractions. In order to study the possibie 
presence of an inhibitor, the extracts of liver and 
muscle were mixed and the assay was performed 
immediately and after 1 h preincubation (table 3). 
The liver hydroxylase activity was unaffected or only 
moderately decreased by the addition of muscle 
extract. In another experiment, he proteins of the 
100 000 X g supernatant fraction of the muscle 
homogenate were concentrated with saturated 
ammonium sulphate before assay. In one of the 
duplicate assays the amount of radioactivity in the 
carnitine fraction was slightly higher (2.4% of 
incubated amount of substrate) than in the blank 
(1 .O%). If this conversion reflects y-butyrobetaine, 
hydroxylase activity it would correspond to spec. act. 
0.05 nkat X (g protein)-‘, i.e., 5 1% of the enzyme 
activity demonstrated inovine liver tissue and < 5% 
of the activity reported ln 191. The reason for the dis- 
crepancy between our results and [9] is not readily 
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Table 3 
Effect of the addition of sheep muscle extracts on the specific activity of r-buty- 
robetaine hydroxylase activity in extracts of sheep liver 
Liver Addition Preincubation Enzyme activity 
sample (mm) nkat X (g protein)-’ 
None 0 7.0 
Muscle extract 0 7.7 
4 None 60 7.1 
Muscle extract 60 7.0 
None 60 7.8 
Muscle extract (ammonium 60 6.7 
sulphate precipitate) 
5 
None 0 
Muscle extract 0 
None 60 
Muscle extract 60 
None 60 
Muscle extract (ammonium 60 
sulphate extract) 
11 
10 
11 
8.3 
11 
7.8 
apparent, since essentially the same incubation proce- 
dures were used. We analyzed the soluble fraction of 
the muscle homogenates a well as [9] ; we also tested 
unfractionated homogenates. Carnitine was deter- 
mined [9] with an enzymatic method, in which the 
formed CoASH was detected with 5,5’-dithiobis-2- 
nitrobenzoic acid [ 181; the technique used here has 
a higher specificity. 
Thus, we found no evidence for the presence of 
soluble or organelle-associated y-butyrobetaine 
hydroxylase in muscle tissue. The results indicate 
that human skeletal muscle carnitine has its origin 
outside the muscle tissue and reaches the skeletal 
muscle by way of the blood stream. 
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